Cancer Therapy Empowered by Extracellular Vesicle-Mediated Targeted Delivery

Biol Pharm Bull. 2023;46(10):1353-1364. doi: 10.1248/bpb.b23-00378.

Abstract

Extracellular vesicles (EVs) are a class of nanoparticles that mediate signaling molecules delivery between donor and recipient cells. Heterogeneity in the content of EVs and their membrane surface proteins determines their unique targetability. Their low immunogenicity, capability to cross various biological barriers, and superior biocompatibility enable engineering-modified EVs to be ideal drug delivery carriers. In addition, the engineered EVs that emerge in recent years have become a powerful tool for cancer treatment through the selective delivery of bioactive molecules to therapeutic targets, such as tumor cells and stroma. Our review focuses on the various types of EV modifications and their promoting therapeutic capabilities, which provide an innovative means for cancer precision therapy.

Keywords: engineered modification; extracellular vesicle; gene editing; targeted delivery.

Publication types

  • Review

MeSH terms

  • Drug Carriers / metabolism
  • Drug Delivery Systems
  • Extracellular Vesicles* / metabolism
  • Membrane Proteins / metabolism
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Signal Transduction

Substances

  • Drug Carriers
  • Membrane Proteins